The diversification of kratom-derived products

Update on the diversification of kratom-derived products: 7-hydroxymitragynine, pseudoindoxyl, and beyond

This talk will provide a background on traditional kratom and an overview of the recent proliferation of novel, kratom-derived products. Industry marketing, media coverage and dynamic government policy will be described, as all influence public health responses. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom, 7-hydroxymitragynine (7-OH), and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks.

Learn more and register

For trainings that indicate Continuing Education Units (CEUs) are available, contact your licensing or certification organization to verify that the credits will count toward the continuing education requirements.